São Paulo government makes billionaire request to double vaccine production

. Aug 27, 2020
vaccine brazil Photo: ADfoto/Shutterstock

Produced by the São Paulo-based Butantan Biological Institute in partnership with Chinese firm Sinovac, the Coronavac vaccine is one of the many prospective inoculations against the coronavirus being tested in Brazil. The initial agreement with Sinovac was to produce 60 million doses by the end of the first quarter of 2021, but the São Paulo state government has requested BRL 1.9 billion (USD 340 million) in funding from the Health Ministry to double this planned output by the end of next year.

Phase three trials on the vaccine began in São Paulo on June 11, and the plan is to test the serum on 9,000 volunteers from around Brazil. Antibody responses from these trials have been positive.

On a national level, President Jair Bolsonaro has been dismissive of the Coronavac initiative, fearing that its success may raise the stock of São Paulo Governor João Doria — one of his leading political rivals.

Support this coverage →Support this coverage →
Euan Marshall

Originally from Scotland, Euan Marshall is a journalist who ditched his kilt and bagpipes for a caipirinha and a football in 2011, when he traded Glasgow for São Paulo. Specializing in Brazilian soccer, politics and the connection between the two, he authored a comprehensive history of Brazilian soccer entitled “A to Zico: An Alphabet of Brazilian Football.”

Our content is protected by copyright. Want to republish The Brazilian Report? Email us at